New Delhi, March 13 (IANS) The price of commonly used diabetes drug empagliflozin has been slashed by almost one-tenth, with the entry of its generic versions in the market.
Developed by German pharma giant Boehringer Ingelheim (BI) empagliflozin, it is sold under the name Jardiance. It is an oral medication that helps control blood sugar in patients with type 2 diabetes.
The drug which costs around Rs 60 per tablet, will now be sold for Rs 5.5 per tablet. It comes as drugmakers Mankind, Alkem, Glenmark launched generic versions of empagliflozin.
In a statement, Mankind Pharma said that its Empagliflozin will now be sold at Rs 5.49 per tablet for the 10 mg variant and Rs 9.90 per tablet for the 25 mg variant.
“We are ensuring that cost is no longer a barrier to access,” said Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma.
Alkem has launched the drug under the brand name Empanorm at nearly 80 per cent less than the cost of innovator products.
“With a patient-centric approach, Alkem has introduced anti-counterfeit security band on the pack of Empanorm, as well as comprehensive patient education information, including basic details on diabetes management in Hindi and English with infographics, and QR codes that provide prescribing information and additional patient education information on diabetes, heart failure, and chronic kidney disease in 11 languages,” Alkem said in a statement.
Mumbai-based Glenmark Pharmaceuticals has also introduced a generic drug of Empagliflozin under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).
“The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage type 2 diabetes with established cardiovascular disease more effectively,” said Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals.
India is known as the diabetes capital of the world with over 10 crore people diagnosed with the lifestyle disease, as per the Indian Council of Medical Research–India Diabetes (ICMR INDIAB) study in 2023.
Lowering the cost of anti-diabetes medicines may be a crucial step in tackling the disease burden.
–IANS
rvt/na
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
